论文部分内容阅读
目的:探讨胸腺肽联合黄芪注射液对病毒性心肌炎患儿的疗效。方法:选择我院2006-01/2009-12病毒性心肌炎患儿80例作为研究对象,随机分为治疗组和对照组各40例,治疗组给予胸腺肽联合黄芪注射液联合治疗,对照组仅给予胸腺肽治疗,观察比较两组的临床疗效及心肌酶谱的变化。结果:治疗组40例中,总有效率97.5%;对照组40例中,总有效率75.0%。两组总有效率比较,差异有显著性(P<0.05)。治疗前,两组的心肌酶谱CK-MB、LDH、cTnI组间比较,差异无统计学意义,治疗后,两组均较治疗前有明显改善,且治疗组的CK-MB、LDH、cTnI分别较对照组比较,差异有显著性(P<0.05)。且治疗组患儿的临床症状消失率明显高于对照组,较对照组较明显改善(P<0.05)。结论:胸腺肽联合黄芪注射液对病毒性心肌炎患儿疗效好,临床症状消失快,降低心肌酶,值得临床推广和应用。
Objective: To investigate the efficacy of thymosin combined with astragalus injection in children with viral myocarditis. Methods: Eighty children with viral myocarditis in our hospital from January 2006 to December 2009 were randomly divided into treatment group (n = 40) and control group (n = 40). The treatment group was given Thymosin combined with astragalus injection, the control group was given only Thymosin treatment, observed and compared the clinical efficacy and changes in myocardial enzymes. Results: The treatment group 40 cases, the total effective rate 97.5%; control group 40 cases, the total effective rate 75.0%. The total effective rate between the two groups, the difference was significant (P <0.05). Before treatment, there was no significant difference in CK-MB, LDH and cTnI between the two groups. After treatment, the two groups were significantly improved compared with before treatment, and CK-MB, LDH, cTnI Respectively, compared with the control group, the difference was significant (P <0.05). The disappearance rate of clinical symptoms in the treatment group was significantly higher than that in the control group, which was significantly improved compared with the control group (P <0.05). Conclusion: Thymosin combined with Astragalus injection in children with viral myocarditis good effect, rapid disappearance of clinical symptoms, reduce myocardial enzymes, deserved clinical promotion and application.